Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibing Deng

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Nature Communications|May 2, 2018
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signaturesZhengyan Kan, Ying Ding, Jinho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Nature Communications|December 3, 2020
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcomeYeon Hee Park, Samir Lal, Jeong Eon Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2013
Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactionsHarma Ellens, Shibing Deng, Joann Coleman, et al.
Nature Genetics|May 13, 2014
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancerKai Wang, Siu Tsan Yuen, Jiangchun Xu, et al.
Genome Medicine|July 20, 2023
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerYeon Hee Park, Seock-Ah Im, Kyunghee Park, et al.
Genome Research|June 22, 2013
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaZhengyan Kan, Hancheng Zheng, Xiao Liu, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Nature Communications|May 2, 2018
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signaturesZhengyan Kan, Ying Ding, Jinho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Nature Communications|December 3, 2020
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcomeYeon Hee Park, Samir Lal, Jeong Eon Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2013
Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactionsHarma Ellens, Shibing Deng, Joann Coleman, et al.
Nature Genetics|May 13, 2014
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancerKai Wang, Siu Tsan Yuen, Jiangchun Xu, et al.
Genome Medicine|July 20, 2023
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerYeon Hee Park, Seock-Ah Im, Kyunghee Park, et al.
Genome Research|June 22, 2013
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaZhengyan Kan, Hancheng Zheng, Xiao Liu, et al.
Pageof 7